Meeting Banner
Abstract #2639

The USPIO GEH121333 as a dual R1 and R2 Contrast Agent for Imaging Response to Anti-angiogenic Therapy

Jana Cebulla1, Eugene Kim1, Dan E Meyer2, Karina Langseth3, Tone F Bathen1, Siver A Moestue1, and Else Marie Huuse1,4

1Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway, 2Diagnostics, Imaging and Biomedical Technologies, Niskayuna, NY, United States, 3GE Healthcare AS, Oslo, Norway, 4Department of Medical Imaging, St. Olavs University Hospital, Trondheim, Norway

Preclinical-phase iron oxide particles (GEH121333), with a high r1/r2 ratio compared to other iron oxide nanoparticles, were used for monitoring vascular response to bevacizumab treatment in ovarian cancer xenografts. Susceptibility contrast MRI using T2 and T2* mapping revealed a treatment induced decrease in blood volume and vessel density, but not in vessel size. Additionally, DCE-MRI using gadodiamide detected a decrease in perfusion and/or permeability. In combination, these two methods provide a comprehensive assessment of anti-angiogenic treatment effects.
Lastly, GEH121333 particles induced a strong signal increase in T1w images, which shows promise for its use also as a positive contrast agent.

This abstract and the presentation materials are available to members only; a login is required.

Join Here